Healthcare -
Biotechnology - NASDAQ - US
$ 1.245
-8.09 %
$ 89.4 M
Market Cap
-0.54
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Zentalis Pharmaceuticals, Inc.
| Revenue | 67.4 M |
| Cost Of Revenue | 0 |
| Gross Profit | 67.4 M |
| Operating Expenses | 259 M |
| Operating Income | -191 M |
| Other Expenses | -25.3 M |
| Net Income | -166 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 67.4 | 0 | 0 | 0 | 0 | 0 | 14 K |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 0 | 1.4 | 1.4 | 0.5 | 0.2 | 0.1 | 0 |
| Gross Profit | 67.4 | (1.4) | (1.4) | (0.5) | (0.2) | (0.1) | 14 K |
| OPERATING INCOME | |||||||
| Operating Expenses | 258.6 | 252.6 | 227.3 | 216.5 | 118.8 | 46.8 | 23.8 |
| Selling, General and Administrative Expenses | 87.1 | 59.4 | 54.6 | 40.9 | 33.9 | 8.5 | 4.9 |
| Research and Development Expenses | 167.8 | 189.6 | 172.7 | 175.6 | 84.9 | 38.4 | 18.9 |
| Operating Income | (191.2) | (249.0) | (227.3) | (216.5) | (118.8) | (46.8) | (23.8) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 0 | 2.6 | 0 | 0 | 0 | 0 |
| Total Other Income | 25.5 | (27.9) | 6.0 | 52.0 | 0.7 | 0.5 | 0.4 |
| Pre-Tax Income | (165.7) | (276.9) | (221.3) | (164.6) | (118.1) | (46.4) | (23.4) |
| NET INCOME | |||||||
| Tax Provision | 0.2 | (0.6) | (0.5) | (0.3) | 0.4 | 15 K | 4 K |
| Net Income | (165.8) | (292.2) | (220.8) | (164.3) | (118.5) | (46.4) | (21.1) |
| EPS | 2.33 | 4.47 | 4.18 | 3.85 | 2.89 | 1.29 | 1.17 |